tsn

Clinical Investigators Focusing on benefits of Reolysin, Kyprolis Combination in Multiple Myeloma

 26876
0 comment
Staff at TrialSite | Quality Journalism
Feb. 1, 2020, 4:30 p.m.

Oncolytics Biotech’s virus-based anti-cancer therapy Reolysin (pelareorep) has the attention of top researchers from Winship Cancer Center and City of Hope who are studying how combinations including pelareorep and Kyprolis (carfilzomib) offer benefits to multiple myeloma patients.

Quality journalism costs money to produce.

Free access provides up to 10 articles

Subscription options start at $5 per month 
which is less than a Starbucks coffee!

Peter Gabriel, MD
"Publishing on TrialSite helped me secure a $20m research grant for my work."
Jona Savinda
"TrialSiteNews is my daily read for what is happening in the industry."
Lucas Van Der Hoven
"Objective, unbiased reporting on the latest news in medical research. I trust TrialSiteNews to give it to me straight."
TrialSiteNews
159 W Broadway, Suite 200
Salt Lake City, UT 84101
© 2025 - Trial Site News